Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...
AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a ...
The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission ...
Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” ...
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
As the field grows rapidly, companies are luring people from other nuclear industries and tapping the expanding educational ...
As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low ...
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that ...
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
The FDA in July last year declined to approve UX111 for Sanfilippo syndrome, a rare neurodegenerative disorder, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results